CervoMed
Price & Volume
Stats
See moreOpen | $4.35 |
Previous Close | $4.40 |
Day Range | $3.97-$4.35 |
52W Range | $1.92-$16.94 |
Market Cap | $40.6M |
Shares Short | 251,455 |
Financials
See moreRevenue (12 Mos) | $6.1M |
Revenue Growth (YoY) | -83.4% |
Gross Profit (12 Mos) | -$16.9M |
Diluted EPS | -$2.90 |
News
See moreYahoo Finance • 3 months ago
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Yahoo Finance • 3 months ago
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
Yahoo Finance • 3 months ago
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Yahoo Finance • 4 months ago
CervoMed reports Q3 results
About
CEO | Dr. John J. Alam M.D. |
CFO | Mr. William Robert Elder J.D. |
Address | 20 Park Plaza, Boston, MA, United States, 02116 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 15 |
